The US biotech company says its experimental drug candidate diranersen, designed to reduce the production of tau in the brain, delivered a clinically meaningful slowing of cognitive decline in patients with early Alzheimer's disease.
The new data come from the open-label extension phase of the study and were presented on Tuesday at the ongoing Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston.